Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

Kai-Ni Shen; Ya-Juan Gao; Long Chang; Lu Zhang; Xin-Xin Cao; Zhuang Tian; Yi-Ning Wang; Dao-Bin Zhou; Jian Li

doi:10.3324/haematol.2024.285145

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

Haematologica. 2024 Jul 1;109(7):2355-2358. doi: 10.3324/haematol.2024.285145.

Authors

Kai-Ni Shen¹, Ya-Juan Gao¹, Long Chang¹, Lu Zhang¹, Xin-Xin Cao¹, Zhuang Tian², Yi-Ning Wang³, Dao-Bin Zhou¹, Jian Li⁴

Affiliations

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
² Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
³ Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
⁴ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. [email protected].

No abstract available

Publication types

Clinical Trial, Phase II
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal* / administration & dosage
Antibodies, Monoclonal* / adverse effects
Antibodies, Monoclonal* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bortezomib* / administration & dosage
Bortezomib* / adverse effects
Bortezomib* / therapeutic use
Dexamethasone* / administration & dosage
Dexamethasone* / adverse effects
Dexamethasone* / therapeutic use
Female
Humans
Immunoglobulin Light-chain Amyloidosis* / diagnosis
Immunoglobulin Light-chain Amyloidosis* / drug therapy
Immunoglobulin Light-chain Amyloidosis* / mortality
Male
Middle Aged
Neoplasm Staging
Prospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal
Bortezomib
daratumumab
Dexamethasone

Grants and funding

Funding: This work was supported by the National Natural Science Foundation of China (grant no. 82200230, to KNS); the National High Level Hospital Clinical Research Funding (grant no. 2022-PUMCH-A-260, to KNS); the CAMS Innovation Fund for Medical Sciences (grant no. 2021-I2M-1-019, to JL); and the National High Level Hospital Clinical Research Funding (grant no. 2022-PUMCH-C-051, to JL); and funding from Xi’an Janssen Pharmaceutical Ltd., Beijing, China.